Investor Education Series
The KC BioHub Investor Education Series is an initiative developed by KC BioHub to support individuals interested in learning more about early-stage investment in life sciences, biotechnology, and related fields.
Designed for accredited angel investors, the program offers a guided introduction to the biotech ecosystem, covering scientific concepts, regulatory processes, due diligence practices, and market trends. Sessions are supported by experienced practitioners, researchers, and investors with direct knowledge of the field.
Whether you’re looking to expand your portfolio or deepen your understanding of emerging technologies in healthcare, agriculture, and bioengineering, this series offers an accessible way to get started.
What the Program Offers
- A foundational overview of biotech, life sciences, and agtech investing
- Live instruction from subject matter experts with real-world experience
- Opportunities for discussion and Q&A in each session
- Optional access to pitch events, lab tours, and networking with regional companies
- A growing peer community interested in science-backed innovation and regional economic growth
Who Should Participate?
This program is intended for accredited angel investors.
Participants do not need prior biotech experience, just curiosity, openness to learning, and an interest in engaging with Kansas City’s growing life sciences ecosystem. The program is open to investors based locally or internationally.
Spring 2026 Curriculum
Apr 2, 2026 – What is biotech?
A clear introduction to biotech as an investable asset class, grounded in both real-world impact and financial opportunity. You’ll understand how innovation moves from lab to market and where investors create leverage in the process.
Apr 9, 2026 – The Role of the Angel Investor in Biotech
A practical look at where angel investors play across the biotech lifecycle, from early proof-of-concept to value inflection points. Learn how capital, timing, and strategic support influence outcomes in a high-risk, high-reward sector.
Apr 16, 2026 – Drug Development, Drug Delivery, & Biomanufacturing
A breakdown of how drugs move from discovery to commercialization, including clinical development, manufacturing, and exit pathways. You’ll see where value is created, where risk accumulates, and what it takes to fund and scale a biotech company.
Apr 23, 2026 – Medical Devices
An examination of how medical devices are developed, regulated, and brought to market. The session highlights how clinical impact, usability, reimbursement, and cost structure influence adoption, scalability, and investor returns.
Apr 30, 2026 – Diagnostics & BioTools
A look at how diagnostics and BioTools companies create value by enabling faster, more accurate insights across clinical care and research. Key drivers include biomarker relevance, throughput, regulatory pathways, and business models that impact scale and adoption.
May 7, 2026 – Digital Health & Health IT
An exploration of how software and data-driven solutions are reshaping healthcare delivery, research, and operations. The session distinguishes digital health, health tech, and tech bio, while highlighting how integration, user experience, reimbursement, and regulation influence outcomes.
